Friedrich Asmus

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Refractory post-surgical cystoid macular edema managed following suprachoroidal microcatheterization and delivery of triamcinolone.

Refractory post-surgical cystoid macular edema managed following suprachoroidal microcatheterization and delivery of triamcinolone.

Journal: BMC ophthalmology

Published: June 13, 2023

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.

Journal: Journal of vitreoretinal diseases

Published: April 03, 2023

INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.

INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.

Journal: Retina (Philadelphia, Pa.)

Published: March 02, 2022

Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial.

Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial.

Journal: Nature medicine

Published: May 27, 2021

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study.

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: October 19, 2019

Development and validation of novel clinical endpoints in intermediate age-related macular degeneration in MACUSTAR

Development and validation of novel clinical endpoints in intermediate age-related macular degeneration in MACUSTAR

Journal: Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft

Published: May 16, 2019

Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.

Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.

Journal: Ophthalmology

Published: December 12, 2018

Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.

Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.

Journal: Ophthalmology. Retina

Published: November 02, 2018

Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study.

Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study.

Journal: Acta ophthalmologica

Published: June 28, 2018

MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration.

MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration.

Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde

Published: March 26, 2018

Integrated results from the COPERNICUS and GALILEO studies.

Integrated results from the COPERNICUS and GALILEO studies.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: September 09, 2017

Psychiatric disorders, myoclonus dystonia and SGCE: an international study.

Psychiatric disorders, myoclonus dystonia and SGCE: an international study.

Journal: Annals of clinical and translational neurology

Published: September 23, 2015

Showing 1-12 of 18

Last Updated: 09/26/2026